Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News NeuroMetrix Inc NURO

Healthcare Medical Devices

NeuroMetrix, Inc. is a commercial-stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two... see more

Add To Watchlist

Recent & Breaking News (NDAQ:NURO)

NeuroMetrix, Inc. Announces Date for Second Quarter 2023 Business and Financial Highlights Conference Call

GlobeNewswire July 20, 2023

NeuroMetrix Announces Sales Force Expansion for Quell Fibromyalgia

GlobeNewswire July 11, 2023

Recent Publications Demonstrate Utility of DPNCheck® for Identifying High-Risk Diabetes Patients

GlobeNewswire June 28, 2023

Diabetic Peripheral Neuropathy Screening That Includes DPNCheck® Predicts Mortality In A Prospective Clinical Study

GlobeNewswire June 7, 2023

Quell® Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy (CIPN)

GlobeNewswire May 31, 2023

NeuroMetrix Reports Q1 2023 Financial Results

GlobeNewswire May 3, 2023

NeuroMetrix, Inc. Announces Date for First Quarter 2023 Financial Results Conference Call

GlobeNewswire April 28, 2023

NeuroMetrix to Exhibit Quell® Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual Meeting

GlobeNewswire March 21, 2023

NeuroMetrix Reports Q4 and Full Year 2022 Financial Results

GlobeNewswire February 23, 2023

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2022 Financial Results Conference Call

GlobeNewswire February 16, 2023

NeuroMetrix® Announces Launch of DPNCheck® 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy

GlobeNewswire January 23, 2023

NeuroMetrix to Introduce Quell® Fibromyalgia at the American College of Rheumatology 2022 Annual Meeting

GlobeNewswire November 8, 2022

NeuroMetrix Announces Strategic Launch of Quell Fibromyalgia

GlobeNewswire November 3, 2022

NeuroMetrix Reports Q3 2022 Financial Results

GlobeNewswire October 20, 2022

NeuroMetrix, Inc. Announces Date for Third Quarter 2022 Financial Results Conference Call

GlobeNewswire October 12, 2022

NeuroMetrix Names Jonathan Breck Harmel as National Director of Sales for its Emerging Prescription Neurotherapeutics Business

GlobeNewswire September 1, 2022

NeuroMetrix Reports Q2 2022 Financial Results

GlobeNewswire July 21, 2022

NeuroMetrix, Inc. Announces Date for Second Quarter 2022 Financial Results Conference Call

GlobeNewswire July 14, 2022

NeuroMetrix Appoints Brad Fluegel to its Board of Directors

GlobeNewswire June 28, 2022

NeuroMetrix Reports that Quell® Wearable Neuromodulation Device has Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia

GlobeNewswire May 19, 2022